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February 3, 2012
Dear Massachusetts Residents,
Every year over 36,000 Massachusetts residents are diagnosed with cancer 
and nearly 13,000 die from cancer. Most of us have been touched by cancer 
whether it is by our own health or that of a friend, neighbor, co-worker or 
family member. Cancer continues to be the leading cause of death in Massa-
chusetts, and impacts some populations more than others. This tells us there 
is much work to be done.
This Comprehensive Cancer Prevention and Control Plan for Massachusetts 
offers an opportunity to work together by increasing our efforts to prevent 
cancer as well as to insure access to care that extends and improves life for 
cancer survivors. This plan addresses several key cross cutting issues; health 
disparities, community engagement and research and evaluation, issues that 
are critically important to our efforts to make a significant difference.
The Massachusetts Cancer Prevention and Control Program (MCCPCP)’s 
Advisory Committee members, and other experts throughout the Common-
wealth, contributed greatly to the development of this plan. This type of  
collaboration is what we envision as we move forward to implement the 
plan. It is only by working together across all communities in the state that 
we will succeed.
We appreciate the commitment from those who helped to prepare this plan 
and look forward to your participation in reducing the burden of cancer in 
our state.
Sincerely,
Cheryl Bartlett 
Chair,  
MCCPCP Advisory Committee
John Auerbach 
Commissioner, 
Massachusetts Department of Public Health
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2executive summary
Massachusetts has been in the forefront of health care reform, resulting 
in far better access to health care for most residents as compared to other 
states. We also have abundant health care facilities and practitioners, and 
good availability to high-quality cancer screening and treatment. Despite 
these advantages, there are still certain population groups in the Common-
wealth who continue to be at higher risk of being diagnosed with and  
dying from cancer than others. This disproportionate cancer burden is  
unacceptable. It will require a focused and unwavering commitment to  
fully address these disparities over the next five years.
Despite the many medical advances in cancer diagnosis and treatment in 
Massachusetts, the increases in obesity and sedentary lifestyle, along with 
unchanged smoking rates, underscore the need for concentrated efforts 
on primary prevention. The increasing evidence of the direct link between 
lifestyle (diet, exercise) and cancer is cause for action. This call to action must 
look to change the environment where people live and work as well as to 
advocate for policies that support people making healthy choices in every 
community across the state.
The 2012–2016 Massachusetts Cancer Plan is a strategic plan to reduce 
the cancer burden in our state. All aspects of the cancer continuum are 
addressed, including prevention, early detection and screening, survivorship, 
treatment, palliation, and end-of-life care, as well as such cross-cutting issues 
as advocacy and community engagement, eliminating disparities, research, 
and surveillance. The Plan’s strategies are intended to direct collective efforts 
toward specific and measurable objectives that will reduce the cancer burden.
Executive Summary   |   3
We must reach out and work collaboratively 
with the array of communities impacted by 
cancer, and use their input and expertise to 
adapt and implement the strategies outlined  
in this plan.
4Specific goals of the Plan are as follows:
Disparities and Health Equity
Reduce the impact of cancer across the Commonwealth while simultane-•	
ously eliminating cancer health disparities and promoting health equity 
in Massachusetts.
Advocacy and Community Engagement
Advocate for actions and resources among government, elected officials, •	
and communities as well as providers, insurers, patients, and families 
to reduce the burden of cancer, particularly where disparities and 
inequities exist. 
Prevention
Create and sustain environments that support the prevention of cancer.•	
Promote behaviors, activities, and policies that reduce the risk of cancer.•	
Early Detection and Screening
Ensure screening for those cancers where strong evidence-based guide-•	
lines for screening currently exist.
Increase informed decision making about cancer screening for cancers for •	
which there is emerging evidence of effectiveness. 
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Survivorship, Treatment, Palliation, and End of Life
Improve the overall experience and quality of life of all Commonwealth •	
residents who are living with, through, and beyond cancer.
Ensure that all Commonwealth residents have equal and timely access to •	
cancer information, treatment, and clinical trials that are based on na-
tionally recognized best-practice standards.
Ensure that Massachusetts residents who have been diagnosed with can-•	
cer can access appropriate palliative care as needed throughout course of 
cancer treatment and after treatment ends.
Ensure that all Commonwealth residents have access to quality end-of-•	
life care.
We live and work in an era of unprecedented cuts in state and federal fund-
ing. Because of this, it is critical that state agencies work in partnership with 
community coalitions, organizations, and leaders. We must reach out and 
work collaboratively with the array of communities impacted by cancer, and 
use their input and expertise to adapt and implement the strategies outlined 
in this plan. Only through such a group effort can we achieve the goals and 
objectives outlined in this plan. Together, we look forward to making this 
cancer plan every Massachusetts community’s cancer plan.
Only through such a group effort can 
we achieve the goals and objectives 
outlined in this plan. Together, we look 
forward to making this cancer plan every 
Massachusetts community’s cancer plan.
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What is Comprehensive  
Cancer Control?
The Centers for Disease Control and Prevention (CDC) defines Comprehen-
sive Cancer Control as “a process through which communities and partner 
organizations pool resources to reduce the burden of cancer. These com-
bined efforts help to reduce cancer risk, find cancers earlier, improve treat-
ments, and increase the number of people who survive cancer.”1  The CDC 
established the National Cancer Prevention and Control Program in 1998 to 
help states, tribes, and territories form coalitions to plan and conduct com-
prehensive cancer control activities. The Massachusetts Department of Public 
Health (MDPH) has been receiving funding for the Massachusetts Compre-
hensive Cancer Prevention and Control Program (MCCPCP) from the CDC 
since 1998.
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The Plan’s strategies are intended to  
direct collective efforts toward specific  
and measurable objectives that will  
reduce the cancer burden.
8What were the accomplishments of the 
2006–2011 Massachusetts Cancer Plan?
Prevention
Tobacco
The Prevention workgroup collaborated with Massachusetts Tobacco •	
Cessation and Prevention Program through various communications 
channels and mass mailings to inform MassHealth recipients of tempo-
rary tobacco cessation coverage. Due to the high utilization rate of this 
temporary benefit with positive results, tobacco cessation was made a 
permanent benefit for MassHealth recipients beginning in July 2009.
The MCCPCP was awarded a five-year cancer prevention policy grant •	
from the CDC, the only state Comprehensive Cancer Control Program 
funded in New England. One of the priority areas for policy intervention 
is tobacco. Working with Voices for a Healthy Southcoast coalition, the 
MCCPCP supported efforts that in March 2011, led to the city of Fall River 
banning the sale of tobacco products in pharmacies.
Nutrition and Physical Activity 
As part of the cancer prevention policy project, the MCCPCP is also in •	
collaboration with the MDPH Nutrition and Physical Activity program, 
working with the Voices coalition on Mass in Motion Initiative (MiM). 
MiM is targeting the development of supportive environments to accom-
modate access to healthy foods and physical activity across the state. The 
target of the cancer prevention policy project is to promote wellness and 
to prevent overweight and obesity in the Southcoast region of Massa-
chusetts, particularly focusing on the importance of healthy eating and 
physical activity.
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Early Detection 
Colorectal Cancer 
In 2009 and 2010, the MCCPCP developed a media campaign targeting •	
Black, non-Hispanic men in Boston and Hispanic men in Springfield. The 
MCCPCP conducted a post-campaign survey, limited to the metropolitan 
Boston area, to assess the campaign’s impact on Black, non-Hispanic men, 
the target audience with the most significant disparate health outcomes. 
Of those who saw a campaign message, 45% talked to their doctor about 
colon cancer and 54% scheduled a colonoscopy.
In 2010, the MCCPCP developed and administered a survey to primary •	
care practices that had already taken steps to improve colorectal cancer 
(CRC) screening and prevention. The results indicated that the majority 
of the small- or medium-sized practices surveyed use Electronic Health 
Records to provide alerts when CRC screening was due or overdue and to 
track abnormal results.
Prostate Cancer 
In 2009, the Brockton Prostate Cancer Work Group created an education-•	
al DVD that shows prostate cancer survivors discussing their experiences 
with the disease and its effect on their family. The DVD is available in 
four languages: English, Portuguese, Haitian Creole, and Spanish.
In January 2011, the MCCPCP conducted a survey among Massachusetts •	
primary care physicians (PCPs) regarding prostate cancer decision-making. 
Its purpose was to assess the extent to which PCPs discuss the decision 
to have prostate cancer screening with their patients, learn how the 
discussion to have the screening is conducted, and learn to what extent 
patients are involved in the decision-making process. Over 70% of PCPs 
reported that they discuss with their patients the advantages and dis-
advantages of prostate cancer screening before ordering the PSA and 
three-quarters of PCPs reported that they made the decision to have the 
screening together with their patients.
10
The MCCPCP has provided funding to the Massachusetts Prostate Can-•	
cer Coalition in the last few years to support the Massachusetts Prostate 
Cancer Annual Symposium. The Symposium covered a range of issues 
including the significance of immunological approaches for prostate can-
cer, information regarding new clinical trials, reviews of prostate cancer 
screening and treatment modalities, information regarding the meanings 
and messages of PSA tests, discussions of proton beam therapy and the 
cyber knife, as well as panels addressing how to increase awareness of 
men’s health and prostate cancer in the Black non-Hispanic community. 
Survivorship
In May 2008, the first Massachusetts Cancer Survivorship Summit was •	
held. Summit participants explored survivorship issues from both a sys-
tems and individual perspective. Two hundred and twenty (220) individu-
als attended the Summit. 
In June 2009, the MCCPCP, in collaboration with its Cancer Survivorship •	
Work Group, conducted a cancer survivorship survey. This survey assessed 
whether oncologists prepare treatment summaries and survivorship care 
plans for cancer patients who have finished treatment, and if PCPs have re-
ceived these treatment summaries and survivorship care plans. Over half of 
the oncologists surveyed reported that they prepare treatment summaries 
and 54% percent of PCPs reported that they have received summaries.
In October 2010, the first New England Regional Comprehensive Cancer •	
Control Survivorship Conference was held. The overall goal of the confer-
ence was to foster a regional collaboration among the six New England 
states on issues related to cancer survivorship. As a result of the confer-
ence, five work groups have been created to discuss ways to avoid dupli-
cation of efforts and leverage scarce resources.
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What is the 2012–2016 Massachusetts 
Cancer Plan?
The 2012–2016 Massachusetts Cancer Plan is a strategic plan to reduce the 
cancer burden in our state. It will update the previous 2006–2011 Massachu-
setts Cancer Plan, which was released in January 2006 and was developed 
through a collaboration of more than 100 academic, government, com-
munity, and survivor organizations dedicated to reducing cancer incidence, 
morbidity, and mortality across the state. 
As in the previous plan, the 2012–2016 Massachusetts Cancer Plan was 
designed to provide guidance to individuals and organizations, spanning 
a wide range of health and social disciplines, which can play a role in pre-
venting and controlling cancer. All aspects of the cancer continuum are 
addressed, including prevention, early detection and screening, survivorship, 
treatment, palliation, and end-of-life care, as well as such cross-cutting issues 
as advocacy and community engagement, eliminating disparities, research, 
and surveillance. The Plan’s strategies are intended to direct collective efforts 
toward specific and measurable objectives that will reduce the cancer bur-
den. Moreover, many of the outcomes will have health benefits extending 
beyond cancer to other leading causes of death such as heart disease and 
diabetes. Massachusetts is committed to this approach and believes that this 
is the best way to successfully reduce both new cases of and deaths from 
cancer in the Commonwealth.2 
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Introduction
The burden of cancer in both the United States and Massachusetts remains 
high. Every day, nearly 100 Massachusetts residents are diagnosed with can-
cer and 36 Massachusetts residents die of cancer, representing a quarter of 
all deaths. In 2008, for the third year in a row, cancer was the leading cause 
of death in Massachusetts, and lung cancer was the leading cause of cancer 
deaths among all cancers.3  The American Cancer Society estimates approxi-
mately 1,596,670 new cancer cases will be diagnosed in the US in 2011, and 
571,950 people will die of cancer, while 37,470 Massachusetts residents will 
be diagnosed with cancer and 12,910 will die of cancer this year.4
In addition to its morbidity and mortality burden, cancer has high economic 
costs. The National Institutes of Health (NIH) estimated that the overall costs 
of cancer in the US to be $263.8 billion in 2010. This includes both direct 
(medical costs) of $102.8 billion and indirect morbidity costs of $20.9 billion, 
and the indirect cost of lost productivity due to premature death ($140.1 bil-
lion).5  In Massachusetts, total state Medicaid expenditures for cancer in 2007 
were $52 million.6 
the burden of cancer 
in massachusetts
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the burden of cancer 
in massachusetts
In addition to its morbidity and 
mortality burden, cancer has  
high economic costs. 
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Cancer Incidence (New Cases)
Among Massachusetts females, breast cancer was the most commonly diag-
nosed cancer from 2003 to 2007, followed by lung, colorectal, and uterine 
cancers (Figure 1). During that period, prostate cancer was the most com-
monly diagnosed cancer in Massachusetts men, followed by lung, colon, and 
bladder cancers. From 2003 to 2007, there were 179,324 newly diagnosed 
cases of cancer in Massachusetts — 90,222 (50.3%) in males and 89,090 
(49.7%) in females.7  The age-adjusted incidence rate for all cancers com-
bined was 598.0 cases/100,000 for males and 458.9 cases/100,000 for females 
(Tables 1 and 2). Massachusetts’ cancer incidence rates were higher than 
national rates (556.5/100,000 in males and 414.8/100,000 in females).
The likelihood of being diagnosed with cancer increases steadily with age 
for many cancers. The age-specific incidence rate for all sites combined for 
males rose from 24.1/100,000 in the 0–4 age group to 3,481.6/100,000 in the 
80–84 age group, and from 25.0/100,000 for ages 0–4 to 2,188.3/100,000 for 
ages 80–84 among females.7 Incidence rates decrease among both males and 
females after age 84.
Figure 1. Cancer Incidence by Type of Cancer and Sex, Massachusetts, 2003–2007
  Males                                                             Females
Prostate
28.1%
Breast
28.3%
Bronchus &
Lung
14.1%
Colorectal
10.2%
Uterus
6.3%
Other
41.1%
Other
40.7%
Urinary
Bladder
7.5%
Bronchus &
Lung
13.7%
Colorectal
10%
Data Source: Massachusetts Cancer Registry, 2010
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Cancer Mortality (Deaths)
Cancer is the leading cause of death in Massachusetts, followed by heart 
disease, stroke, and chronic lower respiratory disease.3 It is the leading cause 
of death for ages 1–14 and 45–84, and second only to heart disease in those 
aged 85 and older. Lung, prostate, colorectal, and pancreatic cancers are the 
leading causes of cancer deaths among males, making up more than half 
(54%) of all cancer deaths in men, while lung, breast, colorectal, and pan-
creatic cancers are the leading causes of cancer deaths in females, compris-
ing 57% of all cancer deaths of women (Figure 2). Between 2003 and 2007 
there were 66,332 deaths due to cancer, with 33,207 (50.1%) deaths occur-
ring among males and 33,125 (49.9%) among females. The age-adjusted 
mortality rate for all cancers combined was 230.1 deaths/100,000 for males 
and 159.1 deaths/100,000 for females (Tables 1 and 2). Massachusetts’ cancer 
mortality rates were comparable to national rates (229.9/100,000 in males 
and 157.8/100,000 in females).
Figure 2. Cancer Mortality by Type of Cancer and Sex, Massachusetts, 2003–2007
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Breast Cancer
Breast cancer was the most commonly diagnosed cancer among Massachu-
setts females between 2003 and 2007, representing approximately 28% 
of all new cancer cases in this group. The age-adjusted incidence rate was 
132.1/100,000, 8% higher than the national rate of 121.8/100,000. The inci-
dence rate of breast cancer in Massachusetts females slightly increased from 
130.6/100,000 in 2003 to 133.5/100,000 in 2007 (Figure 3). However, this 
increase was not statistically significant. 
Between 2003 and 2007, breast cancer was the second leading cause 
of death among Massachusetts females, after lung cancer. It accounted 
for approximately 27% of all cancer deaths in females, with an age-
adjusted mortality rate of 22.9/100,000, comparable to the national rate 
of 24.5/100,000. During this period, breast cancer deaths in Massachusetts 
decreased significantly, from 24.4/100,000 in 2003 to 20.1/100,000 in 2007 
(Figure 3).
Figure 3. Breast cancer incidence and mortality rates by year,  
Massachusetts, 2003–2007
R
at
e 
p
er
 1
00
,0
00
130.6             133.4              130.4               132.3              133.5
160
140
120
100
80
60
40
20
0
24.4               24.0                 22.9                23.1                 20.1
2003                   2004                   2005                   2006                   2007 2003–2007
Incidence
Mortality
132.1
22.9
Data Source: Massachusetts Cancer Registry, 2010
The Burden of Cancer in Massachusetts   |   17
Cervical Cancer
Between 2003 and 2007, invasive cervical cancer represented approximately 
1.2% of all new cancer cases in females. The age-adjusted incidence rate was 
5.9/100,000, 29% lower than the national rate of 8.3/100,000. The incidence 
rate of cervical cancer in Massachusetts females increased from 5.3/100,000 
in 2003 to 7.0/100,000 in 2004 and then remained unchanged through 2007 
(Figure 4). It should be noted; however, that both cervical cancer incidence and 
mortality are highly variable because of the relatively small number of cases 
(about 200 per year) and deaths (about 50 to 55 per year) from the disease. 
Cervical cancer accounted for 1% of all cancer deaths in females between 
2003 and 2007, with an age-adjusted mortality rate of 1.4/100,000, 44% 
lower than the national rate of 2.5/100,000. The mortality rate for cervical 
cancer among Massachusetts women decreased slightly during that time 
period, from 1.3/100,000 to 1.1/100,000 (Figure 4).
Figure 4. Cervical cancer incidence and mortality rates by year,  
Massachusetts, 2003–2007
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Colorectal Cancer
Colorectal cancer was the third most commonly diagnosed type of cancer 
in both Massachusetts males and females between 2003 and 2007, account-
ing for 10% of all cases in both males and females. The age-adjusted inci-
dence rate for colorectal cancer in Massachusetts males was 60.7/100,000, 
comparable to the national rate of 59.0/100,000; the incidence rate among 
Massachusetts females was 44.1/100,000, comparable to the national rate of 
43.6. The age-adjusted incidence rate of colorectal cancer in Massachusetts 
males significantly decreased between 2003 and 2007, from 69.0/100,000 
to 51.8/100,000. The incidence rate of colorectal cancer among Massachu-
setts females also significantly decreased between 2003 and 2007, from 
48.1/100,000 to 40.2/100,000 (Figures 5 and 6). 
Colorectal cancer was the third leading cause of cancer death in Massachu-
setts for both males and females between 2003 and 2007, accounting for 9% 
of all cancer deaths in males and 10% of all cancer deaths in females. During 
this period, state and national age-adjusted mortality rates of colorectal can-
cer were comparable for both males (21.0/100,000 for Massachusetts males 
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vs. 21.9 for US males) and females (14.8/100,000 for Massachusetts females 
vs. 15.4 per 100,000 US females). From 2003 to 2007, colorectal cancer mor-
tality decreased significantly in both Massachusetts males (from 23.3 to 
18.9/100,000) and females (from 15.9 to 13.5/100,000) (Figures 5 and 6).
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 Prostate Cancer
Prostate cancer was the most commonly diagnosed type of cancer in Mas-
sachusetts males from 2003 to 2007, representing 28% of all new cases of 
cancer in males. The age-adjusted incidence rate for prostate cancer was 
164.9/100,000 from 2003 to 2007, 6% higher than the national rate of 
155.5/100,000. The incidence of prostate cancer in Massachusetts rose non-
significantly from 164.6/100,000 males in 2003 to 168.4/100,000 males in 2007 
(Figure 7). 
Prostate cancer was the second leading cause of cancer deaths among 
Massachusetts males between 2003 and 2007, representing 10% of all can-
cer deaths in this group. The overall mortality rate for Massachusetts was 
24.6/100,000, comparable to the national rate of 25.6/100,000. From 2003 
to 2007, Massachusetts deaths due to prostate cancer decreased non-signifi-
cantly from 27.0/100,000 to 23.8/100,000 (Figure 7). 
Figure 7. Prostate cancer incidence and mortality rates by year,  
Massachusetts, 2003–2007
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Lung Cancer
In Massachusetts, lung cancer was the second most commonly diagnosed 
type of cancer in both males and females, accounting for 14% of all can-
cer cases in each sex. The age-adjusted incidence rate for lung cancer was 
83.8/100,000 in males, comparable to the US rate of 86.4 per 100,000; among 
Massachusetts females, the incidence rate was 64.0/100,000, 14% higher 
than the US rate of 55.5/100,000. The age-adjusted incidence rate of lung 
cancer incidence declined non-significantly in Massachusetts males dur-
ing this period, from 84.2 cases per 100,000 males in 2003 to 79.9 cases per 
100,000 in 2007. Among Massachusetts females, incidence rose non-signifi-
cantly from 62.5/100,000 to 63.6/100,000 (Figures 8 and 9).
Lung cancer was the leading cause of cancer death for Massachusetts males 
and females between 2003 and 2007, accounting for approximately 29% of 
all cancer deaths in males and 27% of cancer deaths among females. During 
this period, the age-adjusted mortality rate of lung cancer was 65.3/100,000 
for males, 7% lower than the national mortality rate of 70.5/100,000, 
and 43.7/100,000 for females, 7% higher than the national mortality rate 
of 40.9/100,000. Among Massachusetts males, mortality from lung can-
cer decreased from 67.2/100,000 in 2003 to 62.6/100,000 in 2007; among 
females, it decreased from 45.5/100,000 to 42.9/100,000 (Figures 8 and 9). 
Neither of these decreases was statistically significant. 
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Disparities
Cancer is the leading cause of death in Black, non-Hispanics, Hispanics, and 
Asian, non-Hispanics in Massachusetts, and second only to cardiovascular 
disease among White, non-Hispanics. Among males, both overall cancer inci-
dence and mortality are higher in Black, non-Hispanics than in other racial 
groups. This pattern holds for prostate cancer, for which Black, non-Hispanic 
men had significantly higher incidence and mortality rates than for other 
ethnic groups. Among women, overall cancer incidence is higher among 
White, non-Hispanic women, but overall mortality is higher among Black, 
non-Hispanic women. This disparity is also seen for breast cancer. 
From 2003 to 2007, Black, non-Hispanic males had the highest incidence 
rate of all cancer types combined (631.0/100,000) (Table 1). This rate was 
significantly higher than the rates for Asian, non-Hispanics and Hispanics, 
but not for White, non Hispanics. During the same period White, non-His-
panic females had the highest incidence rate of all cancer types combined 
(470.6/100,000) among all race/ethnicity groups (Table 2). This rate was 
significantly higher than the rates for the other race/ethnicity groups. Asian, 
non-Hispanic females had the lowest incidence rate for all sites combined 
(286.1/100,000). 
From 2003 to 2007, lung cancer was the second leading cancer among 
males in all racial groups, except among Hispanic males, where it was the 
third leading cancer. Black, non-Hispanic men had significantly higher lung 
cancer death rates compared with White, non-Hispanic men, while White, 
non-Hispanic females had significantly higher death rates from lung can-
cer compared with the other racial/ethnic groups. Among other cancers of 
interest, cervical cancer incidence and mortality rates are higher in Black, 
non-Hispanic women than in White, non-Hispanic women. Colorectal cancer 
incidence and mortality are elevated in White, non-Hispanics and Black, non-
Hispanics relative to Asian, non-Hispanics and Hispanics.
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Table 1. Age-adjusted incidence and mortality rates* for selected cancer sites by  
race/ethnicity, Massachusetts males, 2003–2007
Cancer Site All Races
White,  
non-Hispanic
Black,  
non-Hispanic
Asian,  
non-Hispanic
Hispanic
Incidence
All sites 598.0 599.9 631.0 320.3 447.0
Prostate 164.9 158.7 252.9 68.2 161.2
Lung 83.8 85.7 91.3 50.2 39.1
Colorectal 60.7 61.1 56.0 43.0 44.1
Mortality
All sites 230.1 233.4 282.3 129.5 121.5
Prostate 24.6 24.4 50.2 9.0 16.0
Lung 65.3 66.7 77.7 41.1 25.4
Colorectal 21.0 21.4 23.8 9.1 10.1
* Rates are age-adjusted to the 2000 US Standard Population and are per 100,000  
Data Source: Massachusetts Cancer Registry, 2010
Table 2. Age-adjusted incidence and mortality rates* for selected cancer sites by  
race/ethnicity, Massachusetts females, 2003–2007
Cancer Site All Races
White,  
non-Hispanic
Black,  
non-Hispanic
Asian,  
non-Hispanic
Hispanic
Incidence
All sites  458.9 469.4 390.0 296.0 321.6
Breast  132.1 136.3 113.2 75.6 86.1
Lung  64.0 67.0 48.0 30.1 24.0
Colorectal  44.1 44.1 42.9 34.5 35.5
Cervical  5.9 5.6 9.6 6.5 10.0
Mortality
All sites  159.1 162.6 173.4 84.5 84.8
Breast  43.7 45.7 38.2 18.0 10.6
Lung  22.9 23.4 29.7 7.0 12.3
Colorectal  14.8 14.9 17.7 9.0 9.5
Cervical  1.4 1.3 2.5 † †
* Rates are age-adjusted to the 2000 US Standard Population and are per 100,000
† An age-adjusted incidence rate was not calculated when there were fewer than 20 cases or deaths  
in a race/ethnicity group.
Data Source: Massachusetts Cancer Registry, 2010
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emerging issues
Emerging issues include new scientific discoveries, new developments in 
health care, and other topics of interest. New research is constantly emerg-
ing relative to cancer prevention, early detection, treatment, palliation, 
survivorship, and end-of-life care. Therefore as these data becomes available, 
organizations such as the National Cancer Institute (NCI) and the United 
States Preventive Services Task Force (USPTF) update their recommendations 
and guidelines to reflect this latest evidence in best practices standards. In 
Massachusetts we have both an NCI-designated comprehensive cancer cen-
ter, the Dana-Farber/Harvard Cancer Center, and a research center at the 
David H. Koch Institute for Integrative Cancer Research at MIT. The Dana-
Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer 
center in the world. It works in collaboration with its seven cancer research 
institutions, including Beth Israel Deaconess Medical Center, Brigham and 
Women's Hospital, Children's Hospital Boston, Dana-Farber Cancer Institute, 
Harvard Medical School, Harvard School of Public Health, and Massachu-
setts General Hospital to fight against cancer by finding new and innovative 
ways to combat the disease. The DF/HCC works on several research programs 
including: prostate, breast, lung and gynecologic cancers, cancer cell biology, 
cancer risk and disparities, and cancer genetics, to name a few.8 The David 
H. Koch Institute for Integrative Cancer Research’s mission at MIT is to apply 
the tools of basic science and technology to determine how cancer is caused, 
progresses and responds to treatment.9  Emerging issues in cancer prevention 
and control in Massachusetts including early detection and screening guide-
lines, and policy, systems and environmental strategies are discussed below.
Emerging Issues   |   27
New research is constantly emerging  
relative to cancer prevention, early  
detection, treatment, palliation,  
survivorship, and end-of-life care.
28
Screening Guidelines
Cancer screening recommendations have changed within the past two years 
for several cancers. Evidence from population-based interventions has shown 
that previous cancer screening guidelines did not reduce mortality rates. This 
has led the USPTF to change its guidelines for prostate, breast and cervical 
cancer screening. 
The current USPTF recommendation for prostate cancer states that there is 
not enough current evidence to balance the benefits and harms of prostate 
cancer screening for men under the age of 75. The current Massachusetts 
recommendation for prostate cancer is for men to talk to their health care 
providers about the benefits and risks of prostate cancer PSA screening 
before being screened. In October 2011, the USPTF issued a new draft recom-
mendation stating that healthy men should no longer receive a PSA blood 
test to screen for prostate cancer because the test does not save lives overall 
and often leads to more tests and treatments that needlessly cause pain, 
impotence and incontinence. The USPTF is currently reviewing public com-
ments before finalizing their guidelines. 
The previous USPTF guidelines for breast cancer screening recommended 
annual mammograms for women aged 40 and older. Since 2009, the USPTF 
has recommended breast cancer screening every two years for women 50–74 
years of age.  However, this new recommendation does not apply to women 
who are at high risk with a genetic mutation or a history of chest radiation. 
In addition, this recommendation may lead to young women not being 
screened early enough to effectively treat breast cancer, since breast can-
cer tends to be more aggressive among women under 50 years of age than 
among older women. 
USPTF current recommendation for lung cancer reveals that there is insuffi-
cient evidence to recommend for or against screening for asymptotic persons 
for lung cancer. However, findings of the National Lung Cancer Screen-
ing trial have shown that screening can reduce death among lung cancer 
patients through early detection using computed tomography (CT) scan.10 It 
is not clear whether current and former smokers should be screened for lung 
cancer using a CT scan. However, CT scans are not cost effective and may lead 
to many false alarms. New lung cancer screening guidelines will be issued in 
early 2012, which will clarify whether the benefits of lung cancer screening 
outweighs its harms. 
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Policy Systems and  
Environmental Strategies 
Previous research has shown that there is convincing evidence linking diet 
and cancer. According to the World Health Organization, dietary factors 
are estimated to account for nearly 30% of cancers in the US and other 
developed countries, making diet the second most important preventable 
cancer risk factor after tobacco.11 Obesity, overweight and physical inactiv-
ity together are associated with an approximately 20 to 30% of several of 
the most common cancers including, breast, colon, endometrial, kidney 
and esophagus. In addition, there is more evidence that physical activity 
decreases the risk of colorectal cancer. High intake of preserved meat and 
salt-preserved foods has also been known to increase cancer risk. Probable 
factors protective of cancer include consumption of fruits and vegetables, 
and physical activity (for breast cancer). Cancer prevention and control 
efforts are increasingly focused on policies, systems and environmental strat-
egies addressing a wide range of issues including nutrition, physical activity 
and tobacco. For instance, the NCI is currently working on initiatives includ-
ing partnerships with institutes across the National Institute of Health (NIH), 
USDA, CDC, and Robert Woods Johnson Foundation that seek to advance 
research to understand the environmental, policy, and social forces that may 
contribute to the growing obesity epidemic, particularly in populations that 
are at the greatest risk of obesity and its adverse consequences. These obe-
sity prevention efforts will not only help control childhood obesity but will 
also reduce cancer related morbidity and mortality in the United States.12
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goals, objectives 
and strategies
Disparities and Health Equity
Definition
The unequal burden of cancer affects individuals and populations through-
out the cancer continuum. Health equity means that everyone has a fair 
opportunity to live a long and healthy life and includes the opportunity for 
everyone to attain their full health potential. Health equity requires address-
ing social determinants of health—broader social and economic conditions 
under which people live which determine their health, such as income—and 
eliminating health disparities.
Inequity refers to differences that are unnecessary and avoidable and are 
considered unfair and unjust. Addressing social determinants that contrib-
ute to health inequity is an issue of social justice. It requires addressing 
interpersonal, institutional, societal, and internalized forms of racism, sex-
ism, classism, homophobia, as well as other forms of bias and discrimina-
tion. It means striving toward a Commonwealth where all individuals and 
families have a high quality of health services, education, housing, and other 
resources that protect, promote, and preserve their health, regardless of 
who they are or where they live. 
Health disparities are differences in the incidence, prevalence, burden and 
mortality of cancer that exist among population groups based on factors 
including, but not limited to, age, class, culture, education, ethnicity, geo-
graphic location, gender identity or expression, income, language, national 
origin, physical or mental disability, race, religion, sex, sexual orientation, 
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goals, objectives 
and strategies
“Each of us, individually, has the  
power to make a difference in  
eliminating the unequal burden of  
cancer...”13 (The Massachusetts Comprehensive  
Cancer Advisory Committee, February 2011)
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socioeconomic status, wealth or other social conditions. We find that racism 
has an independent influence on all the social determinants of health and 
that racism in and of itself has a detrimental impact on health. We affirm 
that racism and other factors are present in individuals and populations 
simultaneously and often interact in a synergistic manner.
“Each of us, individually, has the power to make a difference in eliminating 
the unequal burden of cancer.  It will require the strength of all of us, col-
lectively, to achieve this goal.”13  (The Massachusetts Comprehensive Cancer 
Advisory Committee, February 2011)
Background
Research has shown that disparities exist in cancer incidence, mortality, and 
survival by race/ethnicity and socioeconomic status. A number of factors 
play a role, including “differences in exposure to underlying risk factors…, 
access to high-quality screening…, and timely diagnosis and treatment for 
many cancers.”14 Black, non-Hispanics have poorer survival rates than White, 
non-Hispanics for every stage at diagnosis, and for almost all cancer sites, 
and non-White populations are, in general, more likely than White, non-
Hispanics to be diagnosed at a later stage of disease. A recent analysis by the 
American Cancer Society9 found that more than a third of premature cancer 
deaths could have been avoided by eliminating educational and racial dis-
parities, with cancer death rates among those with the least education more 
than twice those of the most highly educated. Another ACS study found 
that Black, non-Hispanic and Hispanic women with breast cancer were more 
likely to be diagnosed at a later stage, and were more likely to encounter 
treatment delays.15 The NCI has also found higher socioeconomic status to 
be associated with more favorable survival rates for the most common types 
of cancer, even after adjusting for treatment.16 Incidence and mortality 
rates for cancers related to infectious agents, such as cervical, stomach, and 
liver cancers, are generally higher in non-White populations than in White 
non-Hispanics. Evidence on cancer disparities for lesbian, gay, bisexual and 
transgender persons is limited by a lack of data collection on sexual orienta-
tion and gender identity. However, recent publications found gay men in 
California reporting higher rates of cancer than heterosexual counterparts17 
while lesbian, gay and bisexual people in Massachusetts reported higher risk 
factors for cancer than their heterosexual counterparts including smoking, 
obesity and cardiovascular risk.18 
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Research also suggests that a number of these factors act together. For 
example, the ACS’s research on premature cancer deaths suggested that 
“eliminating socioeconomic disparities in African Americans could potentially 
avert twice as many premature cancer deaths as eliminating racial disparities, 
underscoring the dominant role of poverty in cancer disparities.”9 Race itself 
serves as a “rough proxy for socioeconomic status, culture, and genes,”19 and 
while we can measure differences in health outcome, we cannot fully distin-
guish what factors are involved. 
In this section, we have one primary goal and two objectives. The goal tar-
gets eliminating cancer health disparities while the objectives outline the key 
initiatives that need to be implemented in order to achieve this goal.
DISPARITIES AND HEALTH EqUITy GoAL: 
Reduce the impact of cancer across the Commonwealth while simultane-
ously reducing cancer health disparities and promoting health equity.
Objective 1: By 2016, the MCCPCP, in partnership with the MDPH Office 
of Health Equity, the Massachusetts Health Disparities Council, and other 
organizations, will identify, develop, implement, and evaluate strategies to 
document and reduce cancer-related health disparities and promote health 
equity in Massachusetts. 
Strategies
Seek resources for a comprehensive assessment of the role social determi-•	
nants play in cancer-related health disparities in Massachusetts. 
Prepare a report using a respectful, community-engaged approach to •	
document current state and local level activities addressing cancer-related 
disparities and health equity. These include, but are not limited to, cultural, 
racial, and linguistic competency training, workforce development, reduc-
tion of/addressing of financial barriers, and community outreach. 
Compare, adapt, and implement evidence-based regional and national •	
strategies that have been shown to reduce cancer-related disparities and 
promote health equity.
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Identify, describe, and enhance public and private data repositories con-•	
taining cancer-related information. Identify the gaps in cancer related 
disparities by age, culture, education, ethnicity, geographic location, 
gender identity or expression, income, language, national origin, physical 
or mental disability, race, religion, sex, sexual orientation, socioeconomic 
status, wealth, or other social conditions. 
Objective 2: By 2016, the MCCPCP Disparities/Health Equity Work Group, 
in collaboration with the MDPH Office of Health Equity, will respectfully 
engage appropriate partners to develop and sustain local-level and state-
wide collaboration to reduce cancer-related health disparities and promote 
health equity.
Strategies:
Promote implementation of two or more comprehensive community •	
assessments (similar to the Community Health Assessment of North Cen-
tral Massachusetts20) that detail the extent of health disparities in regions 
across Massachusetts.
Develop a comprehensive dissemination strategy for regional/community •	
assessments, including an Executive Summary that highlights results. 
Implement and evaluate three or more Culturally and Linguistically •	
Appropriate (CLAS)-specific recommended activities.
Promote effective training on cultural and linguistic competency, work-•	
force development, and community outreach by working with health 
care providers, health professionals, educators, payers, and policy makers.
Improve and systematize the monitoring and reporting of cancer-related •	
disparities and make data available, including through the MCCPCP web-
site, www.macompcancer.org.
Identify and address data gaps in order to improve reporting on disparities •	
(e.g., disability status, income, sexual orientation, and socioeconomic status).
Translate and disseminate academic research findings and effective •	
practices in addressing cancer disparities into accessible and user-friendly 
formats, accessible to diverse communities. 
Promote the integration between cancer-related health disparities and •	
health equity with similar work with other disease conditions, health, 
and wellness. 
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Advocacy and  
Community Engagement
Advocacy and Community Engagement are extremely wide-ranging issues 
that touch upon every facet of the continuum of care. 
In order for comprehensive cancer prevention and control to be effective, 
we must:
Create and sustain a cancer policy and legislative agenda that supports •	
projects across the continuum;
Promote legislation and governmental actions that help decrease the •	
burden of cancer; and 
Disseminate information to the general public to increase awareness of •	
cancer policy issues.
We are all affected by cancer. One out of every two men and one out of 
every three women will be diagnosed with cancer at some point in his or her 
life. Thus, we all have a stake in reducing its burden. Whether we are health 
professionals, cancer survivors, researchers, or legislators, we can all advo-
cate for policies that can support the prevention, early detection, and treat-
ment of cancer; improve access to care; and reduce health disparities. 
There is one key goal for this section that speaks to the broad array of part-
ners that need to be engaged. The two objectives specify how to increase 
support for advocacy and the need to use evidenced based strategies.
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ADvoCACy AND CoMMUNITy ENGAGEMENT GoAL:
Advocate for actions and resources among government, elected officials, 
and communities as well as providers, insurers, patients, and families to 
reduce the burden of cancer, particularly where disparities and  
inequities exist. 
Objective 1: By 2016, develop and strengthen partnerships to leverage 
scarce resources in order to align efforts and activities to prevent and reduce 
the burden of cancer.
Strategies:
Develop a Policy Work Group to expand support for advocacy issues •	
by broadening and integrating efforts towards cancer prevention 
and control.
Align the efforts of the Policy Work Group with the MDPH chronic dis-•	
ease integration model, which focuses on policies and system changes 
that affect all chronic diseases and lifestyle choices, resulting in less dupli-
cation of efforts and increased resources, collaboration, communication, 
and effectiveness.
Identify, engage, and educate non-traditional partners to expand sup-•	
port for advocacy issues, especially those groups focused on underserved 
populations that promote health equity.
Expand and engage grassroots advocacy efforts through education, •	
regional meetings, conferences, the MCCPCP website, and social media. 
Objective 2: By 2016, increase the number of evidence-based policy and 
systems changes, including funding, that prevent and decrease the burden 
of cancer in all areas of the cancer continuum.
Strategies:
Inventory policy and system changes to create a baseline to use in track-•	
ing progress.
Build support for policy change through recruitment of key decision-mak-•	
ers in government, nonprofits, the private sector, and the general public, 
including survivors and families representing various geographic, racial/
ethnic, and other vulnerable populations. 
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Ensure that the policy and system changes that are developed improve •	
the health of vulnerable populations.
Recruit municipalities to adopt and implement evidence-based policies •	
and practices.
Identify specific policy and legislative priorities in the annual work plan.•	
Prevention
Cancer prevention involves avoiding exposure to cancer causing substances 
such as nicotine, making lifestyle changes (especially to diet), and detecting 
and treating cancer early.21 Much of the focus in Massachusetts has been on 
reducing tobacco use, since national evidence identifies tobacco exposure 
as the leading preventable cause of death. In addition, there is increas-
ing evidence of the role that poor diet and lack of exercise play in cancer. 
According to the American Cancer Society, 30% of cancer deaths could be 
avoided if people stopped using tobacco, and another one-third of cancer 
deaths can be attributed to poor nutrition, physical inactivity, overweight or 
obesity, and other lifestyle factors.9 Other preventable cancers include those 
associated with infectious disease exposures, such as liver cancer and cervical 
cancer, and environmental or occupational exposures.
This section of the plan focuses on key areas that can prevent or lower the 
risk of cancer, including stopping the use of and exposure to tobacco, main-
taining a healthy diet, staying physically active and reducing exposure to 
infectious agents and environmental and occupational carcinogens. We have 
two primary goals that address the important role of primary prevention:
PREvENTIoN GoALS: 
1. Create and sustain environments that support the prevention of cancer. 
2. Promote behaviors, activities, and policies that reduce the risk of cancer.
Our objectives focus on policy, environmental, and systems changes that will 
allow for more people to benefit from having healthier choices where they 
work and live. These changes include reducing exposure to tobacco, improv-
ing diet and physical activity, reducing carcinogens in the environment, and 
reducing exposures to infectious agents that can cause cancer. Such changes 
can decrease deaths from both cancer and other chronic diseases.
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Tobacco
Tobacco is still the greatest avoidable risk factor for cancer, estimated to con-
tribute to 25–30% of new cases of cancer, and responsible for 22% of cancer 
deaths every year worldwide. Cancers linked to smoking include those of the 
lung, bladder, cervix, esophagus, kidney, larynx, oral cavity, pancreas, stom-
ach, and throat. 
Although rates have declined in Massachusetts over the past ten years, ciga-
rette smoking still remains a problem. In 2010, 14% of adults reported that 
they were current smokers (vs. 20% in 2000), and another 29% were former 
smokers. Current smoking was associated with lower educational attain-
ment, lower household income, and younger age. Nearly two-thirds of cur-
rent smokers indicated that they had tried to quit smoking for one or more 
days during the previous year, and 40% were planning to try quitting in the 
next month. Smoking rates are even higher in young people: in 2009, 16% 
of high school students and 4.2% of middle school students had smoked 
cigarettes in the past 30 days, while 7.9% of high school students had used 
smokeless tobacco and 14.9% had smoked cigars. 
Objective 1: By 2016, reduce cigarette smoking by adults to 12%. (Baseline: 
14% – Data Source: Behavioral Risk Factor Surveillance System (BRFSS), 2010) 
 
Objective 2: By 2016, reduce cigarette smoking by adults insured through 
MassHealth to 24%. (Baseline: 30% – Data Source: BRFSS, 2009)
Objective 3: By 2016, reduce cigarette smoking among pregnant women to 
6.2%. (Baseline: 6.8% – Data Source: Massachusetts Births, 2009) 
Strategies supporting Objectives 1, 2, and 3:
Increase the proportion of Massachusetts residents whose health insur-•	
ance covers evidence-based tobacco dependence treatment at recom-
mended levels (e.g., the MassHealth Cessation Benefit), including all 
FDA-approved cessation medications and behavioral therapies, and elimi-
nate financial barriers to treatment, such as insurance co-payments. 
Adopt the US Public Health Service’s •	 Clinical Practice Guideline for Treat-
ing Tobacco Use and Dependence: 2008 Update22 recommendations for 
clinicians and health care systems in all primary care, specialty (e.g., OB/
GYN), and inpatient settings.
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Identify and address cultural and linguistic barriers to accessing cessation •	
information, resources, and services for population groups that experi-
ence disparities in tobacco use and cessation. 
Advocate for funding for communication/media strategies to promote •	
cessation to both general and specific population groups.
Objective 4: By 2016, reduce the proportion of high school students (grades 
9-12) who are:
Current smokers (smoked at least one cigarette in the last 30 days) to •	
12%. (Baseline: 16% – Data Source: Massachusetts Youth Risk Behavior 
Survey (MYRBS), 2009)
Daily smokers to 3%. (Baseline: 5.1% – Data Source: YRBS, 2009).•	
Objective 5: By 2016, reduce the proportion of high school students who:
Report using smokeless tobacco in the last 30 days to 5%.(Baseline: 7.9% •	
– Data Source: YRBS, 2009) 
Report smoking cigars in the last 30 days to 8%.(Baseline: 14.9% – Data •	
Source: MYRBS, 2009)
Report having their first cigarette before the age of thirteen to 6%.(Base-•	
line: 9.3% – Data Source: MYRBS, 2009) 
Objective 6: By 2016, decrease the percentage of public middle school 
students (grades 6–8) who have smoked in the last 30 days to 3%. (Baseline: 
4.2% – Data Source: MYRBS, 2009) 
Strategies supporting Objectives 4, 5, and 6:
Increase the unit price of cigarettes and establish tax parity between •	
cigarettes and cigars and smokeless tobacco products, which are cur-
rently taxed at lower rates than cigarettes and are thus more affordable 
to young people.
Work to restrict or minimize the impact of storefront advertising of •	
tobacco products. 
Engage young people in statewide and community-based efforts to •	
advance comprehensive tobacco prevention and control policy goals. 
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Objective 7: By 2016, increase the percentage of smokers in households 
where children are present that have a rule against smoking anywhere in 
the home to 75%. (Baseline: 65.3% – Data Source: BRFSS, 2010)
Strategy supporting Objective 7:
Promote adoption of smoke-free policies in multi-unit housing that •	
increase the availability of smoke-free housing in MA communities.
Nutrition and Physical Activity
Poor diet, lack of exercise, and obesity are noted to play an increasing role 
in the development of cancer, contributing to an estimated 40–55% of new 
cancer cases. Persons who are overweight or obese are at elevated risk of 
a number of cancers, including breast, colorectal, endometrial (uterine), 
esophageal and kidney. 
Although Massachusetts has one of the lowest rates of overweight and 
obese23 adults in the US, rates have risen sharply over the past ten years, from 
53% overweight and 17% obese in 2000 to 60% overweight and 24% obese 
in 2010. Even more alarming is the high percentage of middle and high  
school students who are overweight (14–17%) or obese (10–11%), as obese 
teens are significantly more likely to become obese adults. Moreover, obesity 
and poor diet are linked to an increased risk of a number of chronic diseases, 
including heart disease, diabetes, and stroke, with increased obesity putting 
children and adolescents at increased risk of a host of chronic health problems. 
Objective 1: By 2016, reduce the prevalence of obese adults to 22% and of 
overweight adults to 54% by 2016. (Baseline: 60% overweight, 24% obese – 
Data Source: BRFSS, 2010)
Objective 2: By 2016, decrease the percentage of middle and high school 
students who are overweight to 13% or obese to 9%. (Baseline: Middle 
school – overweight 17%, obese 10%; High school – overweight 14%, obese 
11% – Data Source: MYRBS, 2009; Massachusetts Youth Health Survey 
(MYHS), 2009)
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Objective 3: By 2016, increase the proportion of adults who report regular 
moderate physical activity (physical activity five or more sessions per week 
for 30 minutes or more per session, regardless of intensity) to 58%. (Baseline: 
53% – Data Source: BRFSS, 2009)
Objective 4: By 2016, increase the percentage of middle and high school 
students who are physically active for 60 minutes at least five days per week 
to 37%. (Baseline: Middle school, 33%; High school, 34% – Data Source: 
MYRBS, 2009; MYHS, 2009)
Objective 5: By 2016, increase the proportion of adults who consume five or 
more servings of fruit and vegetables per day to 29%. (Baseline: 26% – Data 
Source: BRFSS, 2009)
Objective 6: By 2016, increase the proportion of high school students who 
consume five or more servings of fruit and vegetables per day to 20%. (Base-
line: 19% – Data Source: MYRBS, 2009)
Strategies supporting Objectives 1–6:
Increase the number of municipalities that have implemented plans, policies, •	
or standards to make positive changes to their built environment to sup-
port healthy community design and opportunities for walking and bicycling.
Increase the number of municipalities that have implemented policies or •	
standards to make positive changes to their food environments aimed at 
increasing consumption of, and access to, fruits and vegetables and reduc-
ing the availability of high-energy-dense foods among adults and children 
(such as menu labeling, establishing farmers markets, or creating incentives 
for local convenience stores to offer fresh fruits and vegetables).
Support local community and regional coalition efforts to increase active •	
living spaces for adults and children in communities (such as zoning, road 
design standards, master plans, school settings and project reviews).
Raise public knowledge of basic definitions of serving size and  •	
exercise levels.
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Raise public knowledge of the increased risk of cancer attributable to •	
being overweight or obese, and integrate messaging into existing Mass 
in Motion efforts. 
Support implementation of school nutrition standards.•	
Support policy changes to improve the quality and amount of physical •	
education and activity in schools.
Encourage employers to establish policies that enable employees to incor-•	
porate regular physical activity and healthy eating into their lifestyle.
Environment
According to the American Cancer Society, carcinogens are “substances that 
can cause changes that can lead to cancer. Substances classified as carcino-
gens may have different levels of cancer-causing potential. Some may cause 
cancer after prolonged, high levels of exposure or by short-term exposure 
to highly toxic materials. And, for any particular person, the risk of develop-
ing cancer depends on many factors, including the length and intensity of 
exposure to the carcinogen and the person’s genetic makeup.”24 Leading 
carcinogens, and the cancers with which they are associated, include radon 
(lung cancer), arsenic (cancer of the skin, lungs, urinary bladder, and kidney), 
asbestos (lung cancer and mesothelioma), and polychlorinated biphenyls 
(PCBs) (cancer of the breast, liver, and biliary tract).
Objective 1: By 2016, increase the number of health care providers who 
have an accurate understanding of the role the environment plays in cancer 
risk. (Baseline and Data Source: to be determined)
Strategies:
Conduct two or more Continuing Medical Education programs within the •	
Commonwealth on environmental health and cancer.
Use newer technology (e.g. social media) to expand the distribution of •	
this information to other providers.
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Objective 2: By 2016, increase the number of consumers who are aware of 
and knowledgeable about naturally occurring and man-made (e.g., indus-
trial, manufacturing) cancer-causing substances in the environment by con-
ducting outreach and education activities. (Baseline and Data Source: to  
be determined)
Strategies:
Using existing data sources identify areas across the state with higher lev-•	
els of naturally-occurring cancer-causing substances such as radon, arsenic, 
and uranium.
Identify “environmental justice” populations (as identified by the •	
Massachusetts Executive Office of Environmental Affairs)25 within the 
above communities.
Develop outreach materials for these populations.•	
Working collaboratively with academic groups and other organizations •	
and their tracking systems, promote awareness of safer alternatives to 
reduce occupational/community exposure.
Objective 3: By 2016, increase the number of school officials who are aware 
of the presence of PCB-containing building materials within their school 
buildings. (Baseline and Data Source: to be determined.)
Strategies:
Identify those public schools/buildings in the state most likely to have •	
PCB-containing building materials or lighting fixtures present.
Distribute the Bureau of Environmental Health’s guidance document on •	
PCBs to those school officials at greatest risk of having PCBs in the indoor 
environment.
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Infectious Agents
There are a number of infectious agents (virus and bacteria that can be 
spread from one person to another) that are associated with an increased 
risk of various cancers. Hepatitis B (HBV) and Hepatitis C (HCV) are viruses 
that can cause liver cancer. Human Immunodeficiency Virus (HIV), the virus 
that causes AIDS, can cause an increased risk of cancers such as Kaposi’s sar-
coma and lymphomas. Some types of Human Papillomavirus (HPV) can cause 
cancers of the cervix, anus, vulva, vagina, penis, and head and neck. The H. 
Pylori bacterium is found in the stomach and is associated with an increased 
risk of stomach cancer and ulcers. There are now vaccines to prevent both 
HBV and HPV, which can reduce the rates of liver cancer and cervical cancer, 
respectively. Reduction of HIV infections can help reduce the rate of certain 
lymphomas and Kaposi’s sarcoma, and early diagnosis and treatment of H. 
pylori infections can reduce the likelihood of developing stomach cancer.26 
Objective 1: By 2016, increase the rate of complete HPV vaccine immuniza-
tion (three doses) among girls and women 9-26 years old to 80%. (Baseline: 
49.4% – Data Source: National Immunization Survey, 2009)
Objective 2: By 2016, establish routine vaccination of adolescent and young 
adult males with three doses of HPV vaccine. (Baseline and Data Source: 
None – new recommendation and program)
Strategies supporting Objectives 1 and 2:
Promote the use of HPV vaccine through educational efforts directed at •	
pediatricians and adult-care providers.
Continue to provide HPV vaccine free-of-charge through the Massachu-•	
setts Immunization Program to girls 18 years old or younger who qualify 
for the federal Vaccines for Children Program.
Continue efforts to raise public awareness of the safety and efficacy of •	
HPV vaccine to prevent HPV infection and the cancers with which it is 
associated.
Objective 3: By 2016, promote age-appropriate sexuality education, inclu-
sive of ways of preventing sexually transmitted infection, as part of compre-
hensive health education to a level of 95%. (Baseline: 50% of high school 
students received information about condoms, 89% of high school students 
received information about HIV/AIDS – Data Source: YRBS, 2007)
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Strategies:
In collaboration with the Department of Elementary and Secondary Edu-•	
cation (DESE), continue to support school efforts to provide age-appro-
priate comprehensive health education.
Support DESE efforts to increase the percentage of schools in which stu-•	
dents’ families or community members have helped select and/ or imple-
ment HIV, STD, or teen pregnancy prevention policies and programs.
Objective 4: By 2016, reduce the risk of cancer of the liver by preventing 
chronic hepatitis due to the hepatitis B virus (HBV).
Strategies:
Increase the proportion of newborns getting a birth dose of HBV vaccine •	
by educating birth hospitals about the importance of the birth dose in 
improving rates of vaccine series completion.
Maintain two-year-old HBV coverage at 95% by assuring the public of •	
the efficacy and safety of hepatitis B vaccine, and promoting its full use.
Objective 5: By 2016, reduce the risk of cancer of the liver by increasing the 
proportion of people aware of their positive HCV infection status to 60% 
and to reduce transmission of HCV. (Baseline: 49% – National Health and 
Nutrition Examination Study, 2002-2007)
Strategies:
Promote evidence-based harm reduction through needle exchange •	
programs, increasing the number of municipalities allowing needle 
exchange programs designed to educate injection drug users about infec-
tion prevention, supply sterile needles and syringes, and offer referral to 
substance use treatment.
Promote safer health care practices to reduce exposure of patients and •	
health care workers to hepatitis viruses by enforcement of requirements 
for safer equipment and injury reporting, reducing needle stick injuries 
by at least 40% to 1,875.
Increase substance use treatment for injection drug users by expanding •	
treatment referrals and opportunities. 
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Objective 6: By 2016, decrease the prevalence of HIV-related cancers (e.g., lym-
phoma and Kaposi’s sarcoma). (Baseline and Data Source: to be determined)
Strategy:
Maintain and enhance evidence-based measures and programs to pre-•	
vent HIV infection.
Objective 7: By 2016, address prevention of stomach cancer due to infec-
tion with H. pylori. (Baseline and Data Source: to be determined)
Strategies:
Increase education and outreach to immigrant communities regarding •	
the risk of stomach cancer and ways of preventing it.
Enhance referral and utilization of primary care services to identify per-•	
sons at risk of H. pylori infection and provide testing and treatment.
Early Detection and Screening
Regular screening for some cancers can help to detect them early, which may 
help to reduce their mortality rate. The removal of precancerous growths 
(such as colon polyps or moles) can also prevent some cancers from becom-
ing invasive and potentially spreading to other parts of the body. Fecal 
occult blood tests (FOBT; also called a blood stool test), sigmoidoscopy, and 
colonoscopy are some of the tests and procedures that can detect colorectal 
cancer in its early stages.27 Breast cancer can be detected earlier by mam-
mography and clinical breast exams, and cervical cancer can be detected in 
its earliest stages using the Pap smear. Prostate cancer can be detected using 
the prostate-specific antigen (PSA) blood test and digital rectal exams (DRE), 
but their use is increasingly controversial. 
This section focuses on two different areas: cancers for which there is signifi-
cant evidence for screening (breast, cervical, and colorectal) and those for 
which there is emerging or limited evidence (lung, prostate). Our objectives 
reflect the United States Preventive Services Task Force (USPSTF) recommen-
dations for overall population-based screening. Given the ongoing concerns 
related to the risks and benefits of prostate cancer screening, our main 
emphasis is on informed decision-making with physicians to assess risk. In the 
case of lung cancer, for which there are emerging ways to screen those 
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at highest risk for lung cancer (e.g., smokers); our objective is to monitor 
emerging technology, such as the use of spiral CT scans.
EARLy DETECTIoN AND SCREENING GoALS:
1. Ensure that all Massachusetts residents receive appropriate and timely 
screening for those cancers where strong evidence-based guidelines for 
screening currently exist.
2. Increase awareness of and access to informed decision making for all 
Massachusetts residents about cancer screening for common cancers for 
which there is emerging evidence of effectiveness. 
Breast Cancer
The age at which to begin routine mammography screening has become 
increasingly controversial over the past several years. In 2009, the USPSTF 
recommended that women aged 50–74 who are at average risk* of breast 
cancer receive mammograms every two years, with the need for routine 
screening among women in their 40s to be determined on an individual 
basis. Evidence to support screening among women aged 75 and older was 
deemed insufficient.28 The American Cancer Society continues to support 
routine annual screening of women beginning at age 40, with no age cut-
off.29 The American College of Obstetrics and Gynecology recently changed 
its guidelines to match those of the ACS.30 
The USPSTF recommendation applies to women age 50 or older who are 
not at increased risk for breast cancer because of a known genetic mutation 
(such as BRCA1 or BRCA2) or a history of radiation to the chest.31 
According to the 2010 Behavioral Risk Factor Surveillance System (BRFSS), 
Massachusetts has the highest rate of mammography screening within the 
last two years among both women aged 40 and older (83.6%) and 50 and 
older (87.5%).32 Rates are lower among women with lower educational 
attainment and lower household incomes, and among women in their 40s 
and 80s, and higher among Black, non-Hispanic women. Despite this, how-
ever, Black, non-Hispanic women have an elevated rate of breast cancer 
mortality and late stage at diagnosis.
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Objective 1: By 2016, increase the percentage of Massachusetts women 
ages 50–74 who have had a mammogram in the past two years to 90%. 
(Baseline: 83.6% – Data Source: BRFSS, 2010)
Objective 2: By 2016, decrease the rate of White, non-Hispanic and Black, 
non-Hispanic women diagnosed with late stage (regional and distant) breast 
cancer to 35 per 100,000. (Baseline: White, non-Hispanic women, 43 per 
100,000; Black, non-Hispanic Women, 43 per 100,000 – Data Source: MCR 
2003-2007)
Strategies:
Convene a Breast Cancer Screening Task Force to develop a statewide •	
strategic plan for increasing screening and follow-up on positive findings 
statewide. The plan will include targeted evidence-based interventions 
(such as reducing structural barriers and increasing Patient Navigation) 
to address gaps in populations or geographic locations including, but not 
limited to, racial and ethnic disparities.
Implement small media campaigns educating women on the importance •	
of breast cancer screening.
Work with the Women’s Health Network in conducting formative •	
research with providers and patients regarding risk factors and informed 
decision-making.
Implement formative research with health plans and the Massachusetts •	
Health Insurance Connector Authority to better understand co-pay and 
deductible issues related to breast cancer screening, diagnosis, and treatment.
Survey providers about their knowledge and attitudes towards breast •	
cancer screening guidelines and about barriers and access issues related 
to breast cancer screening and follow-up.
Based on the results of provider surveys, elicit recommendations for influ-•	
encing provider compliance with screening guidelines.
Promote and offer training to health care providers and other health •	
professionals regarding informed decision-making.
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Cervical Cancer
The USPSTF strongly recommends screening for cervical cancer in women 
who have been sexually active and have a cervix. It recommends against 
routinely screening women older than age 65 for cervical cancer if they 
have had three consecutive normal Pap smears and no abnormalities in the 
last ten years and are not otherwise at high risk** for cervical cancer. The 
Task Force also recommends against routine Pap smear screening in women 
who have had a total hysterectomy for benign disease.33 According to the 
National Cancer Institute, “regular screening of appropriate women for cer-
vical cancer with the Papanicolaou (Pap) test reduces mortality from cervical 
cancer. Screening is effective when started within three years after begin-
ning vaginal intercourse and becomes much less effective in women ages 65 
years and older who have recent negative Pap tests.”34 
As with breast cancer screening, Massachusetts has the highest rate of cervi-
cal cancer screening in the nation, with 84.5% of women aged 18 and older 
reporting having had a Pap smear within the past three years. Rates are 
lower among women with lower household incomes and lower educational 
attainment, and are substantially lower among women aged 75 and older. 
Again, although Black, non-Hispanic women had higher rates of screening 
than women of other races, they were significantly more likely to be diag-
nosed at a later stage.
** The American College of Obstetricians and Gynecologists (ACOG) identifies additional risk factors that might justify 
annual screening, including a history of cervical neoplasia, infection with HPV or other sexually transmitted diseases 
(STDs), or high-risk sexual behavior, but data are limited to determine the benefits of these strategies.35 
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Objective 1: By 2016, increase the percentage of women 21 years of age 
and over who have had a Pap test within the past three years to 90%.  
(Baseline: 84.5% – Data Source: BRFSS, 2010)
Objective 2: By 2016, decrease the proportion of Black, non-Hispanic 
women diagnosed with late stage (regional and distant) cervical cancer to 2 
per 100,000. (Baseline: 5.0 per 100, 000 – Data Source: MCR, 2003-2007)
Strategies to support Objectives 1 and 2:
Work with community partners to develop strategies for education and •	
awareness, especially among those women at highest risk of not getting 
screened for and/or being diagnosed with cervical cancer at a late stage.
Use MCR data to identify disparate populations of women who are diag-•	
nosed with invasive cervical cancer, particularly late-stage.
Explore the possibility of using new data sets to identify women who are •	
at higher risk of cervical cancer.
Colorectal Cancer
Screening for colorectal cancer can actually prevent colorectal cancer by 
finding and removing precancerous polyps before they develop into can-
cer. Screening can also detect colorectal cancer at an earlier stage when it is 
more treatable. The USPSTF recommends that health care providers screen 
men and women aged 50–75 for colorectal cancer using fecal occult blood 
testing, sigmoidoscopy, or colonoscopy.36 
Overall, 63.2% of Massachusetts adults aged 50 and older reported hav-
ing had a colonoscopy or sigmoidoscopy within the past five years, and 
18.3% had had a blood stool test within the previous two years. Screening 
rates were lowest in Hispanics, those with less than a high school diploma, 
a household income of less than $25,000, and aged 80 and older. The col-
orectal cancer incidence rate among Black non-Hispanic men who were 
diagnosed in the late stage (regional and distant stages) was 28 per 100,000 
compared to 31 per 100,000 among White non-Hispanic men between 2003 
and 2007.
Objective 1: By 2016, increase screening rates for colorectal cancer to 80% 
for Massachusetts men and women age 50–75 years. (Baseline: 63.2% – Data 
Source: BRFSS, 2010)
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Objective 2: By 2016, decrease the proportion of White, non-Hispanic and 
Black, non-Hispanic men diagnosed with late stage (regional and distant) 
colorectal cancer to 25 per 100,000. (Baseline: White, non-Hispanic males, 31 
per 100,000; Black, non-Hispanic males, 28 per 100,000 – Data Source: MCR, 
2003-2007)
Objective 3: By 2016, decrease the proportion of White, non-Hispanic and 
Black, non-Hispanic women diagnosed with late stage (regional and distant) 
colorectal cancer to 20 per 100,000. (Baseline: White, non-Hispanic females, 
23 per 100,000; Black, non-Hispanic females, 22 per 100,000 – Data Source: 
MCR, 2003-2007)
Strategies:
Implement targeted media campaigns using the most appropriate chan-•	
nels of delivery for each target group, and delivered by a voice/person 
recognized within the community, to increase awareness and education 
about colorectal screening.
Reduce structural barriers through outreach programs such as Patient •	
Navigation.
Identify practices with low screening rates and assist them in develop-•	
ing office policies and quality improvement initiatives utilizing strategies 
outlined in the American Cancer Society’s document How to Increase 
Colorectal Cancer Screening Rates in Practice: A Primary Care Clinician’s 
Evidence-Based Toolbox and Guide.37 
Promote use of Client Reminders (e.g., mail, telephone) throughout •	
medical practices, community health centers, and health plans utilizing 
an electronic tracking system.
Support legislation that requires insurers to offer the full menu of recom-•	
mended screening options for colorectal cancer screening.
Ensure health plans use evidence-based guidelines for screening.•	
Conduct formative research to better understand what screening options •	
providers are recommending to their patients. 
Assess colorectal cancer screening capacity statewide.•	
Assess endoscopy sites’ quality of screening and reporting.•	
Assess follow-up with primary care providers.•	
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Prostate Cancer
Like mammography, screening for prostate cancer has become increasingly 
controversial due to concerns regarding whether the benefits of the screen-
ing outweigh the risks. The USPTSF has concluded that there isn’t enough 
current evidence to assess this balance in men younger than age 75, and 
recommends against screening in men aged 75 and older. They note that 
prostate cancer treatment can cause problems such as impotence and incon-
tinence, and some men who are diagnosed with prostate cancer have a slow-
growing form of the disease that would never have caused them any trouble. 
Additionally, the PSA test, like other screening tests, may indicate that a man 
has prostate cancer when he doesn’t, leading to pain and discomfort from 
needed procedures as well as stress and worry and long-term complications.38 
According to the BRFSS, 60% of Massachusetts men aged 50 and older 
reported having a PSA test in the past year, and 64.4% had had a DRE. Overall, 
71% had discussed the risks of benefits of screening with their health care pro-
vider. Discussion rates were comparable to the overall rate for White, non-His-
panic and Black, non-Hispanic men, but were significantly lower for Hispanic 
(39.8%) and Asian, non-Hispanic (40.2%) men. Screening and discussion rates 
were lower for less educated men and those with lower household incomes. 
Objective 1: By 2016, increase the number of men age 50 years and older 
who have discussed the risks and benefits of prostate cancer screening with 
their health care providers to 78%. Men at higher risk, such as those of Afri-
can descent or with a family history of prostate cancer, should start discuss-
ing this issue at age 45. (Baseline: Overall, 71%; White, non-Hispanics, 73%, 
Black, non-Hispanics, 72% – Data Source: BRFSS, 2008)
Strategies:
Develop a Prostate Cancer Work Group to monitor emerging science •	
regarding informed decision making and prostate cancer screening.
Promote and offer training to health care providers and other health •	
professionals regarding informed decision-making. 
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Explore and identify evidence-based strategies for informed decision-•	
making through telephone interviews and other modalities. Design, test, 
and evaluate a small media campaign to educate Black, non-Hispanic men 
regarding prostate cancer through community and faith-based partners.
Continue Community Health Worker (CHW) outreach to Black, non-•	
Hispanic men to educate them on their risk factors and the need for 
informed decision-making with their health care provider.
Lung Cancer 
The National Lung Cancer Screening Trial was halted in November, 2010 
when the mortality benefit in the CT arm exceeded the defined end point of 
20%. The challenge now is to weigh the population level benefits and risks 
of lung cancer screening against any individual’s potential benefit along 
with other concerns. Therefore during the next five years it will be critical to 
review existing and emerging evidence in considering recommendations for 
screening programs especially at risk populations.
Objective 1: By 2016, decrease lung cancer mortality rates to 59/100,000 
for men and 39/100,000 for women. (Baseline: Males 65.3/100,000, Females 
43.7/100,000 – Data Source: MCR, 2003-2007)
Strategies:
Create a Lung Cancer Work Group to monitor emerging lung cancer screen-•	
ing guidelines and to establish recommendations for screening programs. 
The Lung Cancer Work Group should be actively engaged in reviewing cost-
benefit analyses necessary prior to recommending population level screen-
ing based on positive findings of the study of high risk individuals.
Actively integrate cessation programs into the protocols for current •	
smokers who are screened for lung cancer.
Design outreach, educational tools, small media and other communica-•	
tion strategies that target those who are at disproportionate risk for lung 
cancer incidence and mortality (e.g., veterans, Black, non-Hispanic males, 
people of color, persons of low socioeconomic status, and immigrants 
and their providers. 
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Survivorship, Treatment,  
Palliation, and End of Life
Survivorship
Thanks to improvements in early detection and treatment, the number of 
cancer survivors continues to increase, both nationally and in Massachusetts. 
According to the Institute of Medicine (IOM), the number of cancer survivors 
in the US has more than tripled in the past 35 years.39 The American Cancer 
Society estimates that more than 11 million people in the United States are 
cancer survivors, and more than two-thirds of persons diagnosed with cancer 
now survive five or more years after diagnosis.4 In the 2010 BRFSS, 9% of all 
Massachusetts adults surveyed, and 25% of those aged 65 and older, reported 
that they had been diagnosed with cancer at some point in their lives.
This rapidly increasing number of cancer survivors is a critical emerging pub-
lic health issue. Increased numbers and longer survival times mean that more 
survivors will be receiving long-term cancer-related care via their primary 
care providers (PCPs), who may not be familiar with recommended standards 
of care. The IOM notes that “…the current US health care system is failing to 
deliver the comprehensive and coordinated follow-up care cancer survivors 
deserve. Too many survivors are lost in transition once they finish treatment. 
They move from an orderly system of care to a ‘non-system’ in which there 
are few guidelines to assist them through the next stage of their life or help 
them overcome the medical and psychosocial problems that may arise.”
A 2009 study40 conducted for the MCCPCP found that treatment summa-
ries and survivorship care plans are not used regularly for cancer survivors 
in Massachusetts. The IOM report especially recommends use of survivor-
ship treatment summaries and care plans to improve quality and continuity 
of care for survivors as they leave oncology care and are followed by PCPs. 
Increasing focus is being placed on survivorship plans from an institutional 
perspective; the American College of Surgeons Commission on Cancer (CoC)’s 
2012 Cancer Program Standards will include a new standard requiring the 
completion and provision of comprehensive care summary and follow-up 
plans to patients upon the completion of treatment.41
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SURvIvoRSHIP, TREATMENT, PALLIATIoN, AND END oF LIFE GoAL: 
Improve the overall experience and quality of life of all Commonwealth  
residents who are living with, through, and beyond cancer.
Objective 1: By 2016, ensure that all cancer survivors in the Commonwealth, 
including disparate populations, have access to appropriate medical, preven-
tive, and dental services.
Strategies:
Continue to support the inclusion of Cancer Survivorship Module ques-•	
tions on the BRFSS Survey to gather information on cancer survivors  
in Massachusetts.
Continue to collaborate with hospitals to disseminate survivorship infor-•	
mation and resources to patients and their caregivers and adapting them 
as needed.
Collaborate with other New England states on common approaches to •	
respond to the results of needs assessments of cancer survivors.
Objective 2: By 2016, enhance the use of treatment summaries and care 
plans in cancer survivors.
Strategies:
Promote legislation to require health care facilities to provide cancer •	
patients with treatment summaries and care plans.
Continue to provide administrative and logistical support for the six New •	
England states’ regional subcommittee working on treatment summaries 
and care plans.
Collaborate with other cancer control partners in adoption and imple-•	
mentation of CoC standards on treatment summaries and care plans. 
Monitor and analyze BRFSS data on cancer survivorship.•	
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Treatment
Massachusetts is home to one of 40 NCI Comprehensive Cancer Centers, the 
Dana-Farber/Harvard Cancer Center, as well as 45 cancer programs accred-
ited by the CoC. These facilities must meet best-practice standards related to 
diagnostic, treatment and other clinical, rehabilitation, support, prevention 
and early detection services. In 2006, 61% of Massachusetts hospitals were 
accredited by CoC, ranking seventh in the US.42 
TREATMENT GoAL:
Ensure that all Commonwealth residents have equal and timely access to 
cancer information, treatment, and clinical trials that are based on nation-
ally recognized best-practice standards.
Objective 1: By 2016, increase the percentage of cancer patients that 
receive first course of treatment at National Cancer Institute (NCI) - or Com-
mission on Cancer (CoC)-accredited hospitals in Massachusetts to 74%. (Base-
line: 72% – Data Sources: NCI, CoC, 2008)
Strategies:
Use MCR data to monitor the proportion of cancer patients that are •	
receiving their care at accredited hospitals.
Collaborate with NCI and CoC to inform consumers of the importance of •	
receiving their cancer treatment care at an accredited hospital.
Pursue a collaborative agreement to share the National Comprehensive •	
Cancer Network (NCCN) patient information portal with patients in Mas-
sachusetts/New England.
Work with CoC-accredited hospitals to enforce Standard 6.1 (•	 Support 
services are provided on site or coordinated with local agencies and facili-
ties.) in their assessment of support services and resource information 
needs for cancer patients.
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Objective 2: By 2016, assess the enrollment of patients in clinical trials. 
Based on this number, increase the percentage of patients that are enrolled 
in a clinical trial to 4%. (Baseline: 2% – Data Sources: CoC, 2010)
Strategies:
Collaborate with the NCI and hospitals to increase the proportion of •	
patients enrolled in clinical trials.
Increase awareness of clinical trials among physicians and cancer survivors, •	
especially those in underserved populations, through the MCCPCP web-
site, via social media outlets, and through printed materials distributed 
to newly diagnosed cancer patients, in collaboration with ACS, CoC Physi-
cian Liaisons, and the Massachusetts Medical Society. 
Disseminate clinical trials information in multiple languages, based on •	
community needs, through hospitals and treatment centers.
Monitor clinical trials knowledge and participation annually through  •	
the BRFSS.
Palliative Care
According to the Massachusetts Expert Panel on End-of-Life Care, “pallia-
tive care refers to medical and other efforts to relieve suffering and improve 
quality of life for patients with serious advancing illness, including efforts 
that are provided at the same time as curative or life-prolonging treat-
ments….studies have…demonstrated multiple benefits of palliative care 
services for patients with serious advancing illness and their families, includ-
ing reduction in pain and other symptoms, improvements in communica-
tion, better emotional and spiritual support, and receipt of care in a setting 
preferred by the patient.”43 
PALLIATIvE CARE GoAL:
Ensure that Massachusetts residents who have been diagnosed with can-
cer can access appropriate palliative care through treatment and beyond, 
including end of life.
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Objective 1: By 2016, in collaboration with the American Cancer Society, 
assess compliance with NCI and CoC standards for palliation. (Baseline: TBD 
(No data at this time) - American Cancer Society)
Strategy:
Ensure NCI and CoC facilities inform their patients about palliative care •	
services based on standards/guidelines. 
Objective 2: By 2016, inventory palliative care practices and measures at 
accredited Massachusetts facilities.
Strategies: 
Assess the utilization of palliative care among cancer survivors, including •	
among members of disparate populations.
Review results of palliative care and quality-of-life studies on a state and •	
national level.
End-of-Life Care
The Massachusetts Expert Panel on End-of-Life Care defines hospice services 
as including “medical, social, emotional, and spiritual support tailored to 
the patient’s needs and wishes.”37 Hospice services are distinct from pallia-
tive care in several ways: first, coverage is generally limited to those with an 
expected life expectancy of six months or less; second, it includes support 
provided to family members and loved ones, including bereavement care. 
The Panel’s 2010 report Patient-Centered Care and Human Mortality: The 
Urgency of Health System Reforms to Ensure Respect for Patients’ Wishes 
and Accountability for Excellence in Care addressed the need for reform 
around the issue of end-of-life care. Research conducted for the report indi-
cated that while two-thirds of Massachusetts residents express a desire to die 
at home, fewer than a quarter do, while more than 70% die in hospitals or 
nursing homes. Although the Commonwealth has made a start in creating 
the Massachusetts on End-of-Life Care, establishing the Expert Panel, and 
developing this report, work remains to be done. 
There is a need for equal access to palliative and hospice care services among 
all patient populations, especially those with known disparities in access-
ing end-of-life care. Previous research has shown lower use of hospice care 
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in Black patients, and a recent study conducted at the Dana-Farber Cancer 
Institute showed that Black patients with advanced cancer were less likely to 
have their wishes regarding end-of-life care honored than White patients.44 
Additionally, not all MassHealth insurance plans cover hospice care. 
END-oF-LIFE CARE GoAL:
Ensure that all Commonwealth residents have access to quality end-of-life 
care in a timely manner.
Objective 1: By 2016, increase hospice services average length of stay to 65 
days statewide. (Baseline: 61 days – Data Source: Hospice & Palliative Care 
Federation of Massachusetts, 2010)
Strategy:
Advocate for credible coverage for hospice benefit from all insurance •	
providers.
Objective 2: By 2016, increase the percentage of cancer patients who use 
hospice care in the last 90 days of life to 38%. (Baseline: 36% – Data Source: 
Hospice & Palliative Care Federation of Massachusetts. 2010)
Strategies:
Develop a mechanism to provide patients and family members with •	
information on hospice care in a timely manner.
Conduct an inventory of health plans to assess coverage of hospice services.•	
Assess use of hospice services by basic demographics, including age, geog-•	
raphy, race, and insurance status.
In collaboration with partners, increase awareness about the availability •	
of hospice services.
Work with hospice providers on cultural competency.•	
Work with the CoC to propose a standard for hospice and end-of-life •	
services.
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research and evaluation
The main goal of the research and evaluation section is to highlight the role 
of cancer data to support the implementation, surveillance, and evaluation 
efforts of the 2012–2016 Massachusetts Cancer Plan. This will be accom-
plished through the use of established cancer surveillance systems, the evalu-
ation of cancer intervention projects, and the timely dissemination of cancer 
burden data and research findings across the continuum. Timely, high qual-
ity, and complete cancer data are essential in reducing the cancer burden. In 
addition, cancer data can be used to plan and target cancer prevention and 
control interventions. The Plan is an evolving document that will continue 
to implement its interventions and activities based on the most current data 
and research findings as they become available. There are 10 goals and 44 
objectives in the Plan and performance measures have been created to moni-
tor and evaluate the Plan based on these objectives. Most interventions will 
be evidence-based or evidence informed. 
National Surveillance Systems
Research and evaluation are essential components of effective, comprehensive 
cancer control. Cancer surveillance is the ongoing process of systematic and 
timely collection and analysis of cancer data including incidence, mortality, 
risk factors, screening, early detection, treatment, and survival.45 The two main 
systems for monitoring and tracking cancer incidence and behavior data are 
cancer registries and the Behavioral Risk Factor Surveillance System (BRFSS). 
The CDC‘s National Program of Cancer Registries (NPCR)46 supports central 
cancer registries and the use of registry data in nearly every state (including 
Massachusetts), the District of Columbia, and some US territories. (Remain-
ing states are funded by the NCI.) These registries collect data on cancer 
incidence by type of cancer, stage at diagnosis, and treatment received. 
As required by law, hospitals, physicians’ offices, surgical centers, thera-
peutic radiation facilities, and pathology laboratories report these data 
to the statewide cancer registry. Some registries also collect survival data. 
Public health professionals use cancer registry data to assess and address 
the burden of cancer and to guide and monitor cancer prevention, control, 
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Timely, high quality, and  
complete cancer data are  
essential in reducing the  
cancer burden.
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treatment, and research.39 Registry data also can be used to determine and 
address disparities in cancer incidence, mortality, and treatment based on 
demographic characteristics including race, age, sex, socioeconomic status, 
and location. 
The Behavioral Risk Factor Surveillance System (BRFSS)47 is a state-based 
system of health surveys that collects data on emerging public health issues, 
health conditions, risk factors, and behaviors. It was established in 1984 by 
the CDC. Currently all 50 states, the District of Columbia, and several US ter-
ritories collect monthly data using the BRFSS. The BRFSS is the only available 
source of timely, accurate data on health-related behaviors for most states. 
More than 350,000 adults nationally and 16,000 adults in Massachusetts are 
interviewed each year, making the BRFSS the largest telephone health sur-
vey in the world. These data are used to identify emerging health problems, 
establish and track health objectives, and develop and evaluate public health 
policies and programs. In addition, many states also use BRFSS data to sup-
port health-related legislative efforts.48
Surveillance in Massachusetts 
Massachusetts surveillance data used in the Plan are from four main sources: 
the Massachusetts Cancer Registry, the Behavioral Risk Factor Surveillance 
System, the Youth Risk Behavior Surveillance System, and the Massachusetts 
Youth Health Survey. 
The Massachusetts Cancer Registry (MCR)49 is part of the MDPH and receives 
funding from the CDC/NPCR. It has been collecting data on all newly diag-
nosed cases of cancer in the state since 1982. These data provide important 
information for monitoring the impact of environmental and occupational 
hazards in Massachusetts. In addition, they are used when designing and 
evaluating cancer prevention and control programs. The MCR publishes 
two annual reports, Cancer Incidence and Mortality in Massachusetts and 
the City/Town Supplement series, as well as special publications focused on 
specific cancer types and populations. The MCR is nationally recognized by 
the North American Association of Central Cancer Registries for meeting the 
highest standards of data quality, completeness, accuracy, and timeliness. 
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The Massachusetts Behavioral Risk Factor Surveillance System (BRFSS)50 is 
conducted by the MDPH Health Survey Program (HSP). BRFSS data are useful 
in identifying the need for health interventions, monitoring the effective-
ness of interventions programs, developing health policy and legislation, and 
measuring progress toward attaining state and national health objectives 
such as Healthy People 2020. The HSP publishes an annual statewide report, 
A Profile of Health Among Massachusetts Adults, periodic reports on Com-
munity Health Network Areas (CHNAs) and specific cities and towns, and 
topical reports and publications. 
Data on Massachusetts youth are collected through two survey instruments, 
the federal Youth Risk Behavior Survey (YRBS)51 and the Massachusetts Youth 
Health Survey (YHS),52 which are administered in alternating years. The YRBS 
is administered by the Massachusetts Department of Elementary and Second-
ary Education (DESE), while the YHS is conducted by the MDPH Health Sur-
vey Program in collaboration with DESE. The YRBS surveys students in grades 
9–12 and the YHS surveys grades 6–12. These surveys collect data on behav-
iors and conditions related to the health, safety, and wellbeing of young 
people across the Massachusetts. These behaviors include tobacco, alcohol, 
and other drug use; behaviors leading to injuries; dietary behaviors and 
physical inactivity; and sexual behaviors. In addition, the two surveys collect 
data on the prevalence of health-related conditions such as obesity, chronic 
diseases, oral health problems, and mental health concerns.
Program Evaluation
Program evaluation is defined as a systematic collection of information 
about program activities, characteristics, personnel and outcomes in order to 
make necessary decisions about the program.53  It is a critical component of 
comprehensive cancer control efforts. The MCCPCP will develop a detailed 
evaluation plan to evaluate the Plan, consistent with the Framework for 
Program Evaluation in Public Health developed by the CDC54. This framework 
is composed of six steps that provide guidance in the evaluation of public 
health programs. These steps include: engaging stakeholders, describing the 
program, focusing the evaluation design, gathering credible evidence, justi-
fying conclusions, and ensuring the use and sharing of lessons learned. The 
framework is non-prescriptive and was designed to summarize and organize 
these essential elements of program evaluation. The six steps outlined in the 
CDC’s framework are similar to the five steps recommended by Cancer Con-
trol P.L.A.N.E.T.55 
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Evidence-Based Interventions
In order to achieve the goals and objectives outlined in the Plan, each strat-
egy listed under the objectives is evidence-based and references are pro-
vided to document the source of the strategy. (If the selected strategy was 
not based on existing evidence, a description of the rationale for choosing 
that strategy is also provided. These strategies are generally referred to as 
evidence-informed strategies.) Sources for evidence-based strategies include:
The US Preventive Services Task Force rigorously evaluates clinical re-•	
search in order to assess the merits of preventive measures, including 
screening tests, counseling, immunizations, and preventive medications.56 
The Community Guide to Preventive Services•	  is a resource for evidence-
based task force recommendations and findings about what works to 
improve public health. It is based on a scientific systematic review process 
and provides up-to-date syntheses of the science examining various inter-
vention strategies.57 
Research-Tested Intervention Programs•	  is a searchable database of cancer 
control interventions and program materials and is designed to provide 
program planners and public health practitioners with easy and immedi-
ate access to research-tested materials.58 
Best Practices for Comprehensive Tobacco Control•	  is an evidence-based 
guide to help states plan and establish effective tobacco control pro-
grams to prevent and reduce tobacco use.59 
The •	 Cancer Control P.L.A.N.E.T portal provides access to data and re-
sources that can help planners, program staff, and researchers to design, 
implement, and evaluate evidence-based cancer control programs.49
The Cochrane Reviews•	 , part of the Cochrane Collaboration are systematic 
reviews of primary research in human health care and health policy, and 
are internationally recognized as the highest standard in evidence-based 
health care.60 
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Performance Measures
The MCCPCP Advisory Committee has identified performance measures to 
monitor the burden of cancer in the Commonwealth and ultimately evaluate 
the effectiveness of the Plan. Progress toward each measure will be reported 
regularly to the Advisory Committee, the CDC, and as other interested par-
ties. These performance measures mirror the continuum of care and cross-
cutting sections covered in the Plan and are listed in the Appendix.
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Health Disparities and Health Equity
Performance Measures Baseline 2016 Target
By 2016, the MCCPCP, in partnership with the MDPH Office of Health 
Equity, the Massachusetts Health Disparities Council, and other organiza-
tions, will identify, develop, implement, and evaluate strategies to docu-
ment and reduce cancer-related health disparities and promote health 
equity in Massachusetts. 
By 2016, the MCCPCP Disparities/Health Equity Work Group, in collabo-
ration with the MDPH Office of Health Equity, will respectfully engage 
appropriate partners to develop and sustain local-level and statewide 
collaboration to reduce cancer-related health disparities and promote 
health equity. 
Advocacy and Community Engagement
Performance Measures Baseline 2016 Target
By 2016, develop and strengthen partnerships to leverage scarce 
resources in order to align efforts and activities to prevent and reduce 
the burden of cancer.
By 2016, increase the number of evidence-based policy and systems 
changes, including funding, that prevent and decrease the burden of 
cancer in all areas of the cancer continuum.
appendix: 
performance measures
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Prevention 
Tobacco
Performance Measures Baselinea 2016 Targetb 
By 2016, reduce cigarette smoking by adults to 12%.  14.0% 12.0%
By 2016, reduce cigarette smoking by adults insured through 
MassHealth to 24%.
 30.0% 24.0%
By 2016, reduce cigarette smoking among pregnant women to 6.2%.  6.8% 6.2%
By 2016, reduce the proportion of high school students who are current 
smokers (smoked at least one cigarette in the last 30 days) to 16%.
 16.0% 12.0%
By 2016, reduce the proportion of high school students who are daily 
smokers to 3%.
 5.1% 3.0%
By 2016, reduce the proportion of high school students who report 
using smokeless tobacco in the last 30 days to 5%.
 65.3% 75.0%
By 2016, reduce the proportion of high school students who report 
smoking cigars in the last 30 days to 8%. 
 14.9% 8.0%
By 2016, reduce the proportion of high school students who report hav-
ing their first cigarette before the age of 13 to 6%.
 9.3% 6.0%
By 2016, decrease the percentage of public middle school students, 
(grades 6–8) who have smoked in the last 30 days to 3%  
 4.2% 3.0%
By 2016, increase the percentage of smokers in households where 
children are present that have a rule against smoking anywhere in the 
home to 75%.
 65.3% 75.0%
aUnless noted otherwise, all adult baselines are based on Massachusetts BRFSS data. 
b2016 Targets are based on Healthy People 2020 goals. 
cMassachusetts Births, 2009 
dUnless noted otherwise, all youth baselines are based on Massachusetts YRBS and YHS data.
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Nutrition and Physical Activity
Performance Measures Baseline 2016 Target
By 2016, reduce the prevalence of overweight adults to 54%. 60.0% 54.0%
By 2016, reduce the prevalence of obese adults to 22%. 24.0% 22.0%
By 2016, decrease the percentage of middle and high school students 
who are overweight to 13%. 
Middle School 
High School
17.0%
14.0%
13.0%
13.0%
By 2016, decrease the percentage of middle and high school students 
who are obese to 9%. 
Middle School    
High School
10.0%
11.0%
9.0%
9.0%
By 2016, increase the proportion of adults who report regular moderate 
physical activity (physical activity five or more sessions per week for 30 
minutes or more per session, regardless of intensity) to 58%.
53.0% 58.0%
By 2016, increase the percentage of middle and high school students 
who are physically active for 60 minutes at least five days per week  
to 37%. 
Middle School 
High School
33.0%
34.0%
37.0%
37.0%
By 2016, increase the proportion of adults who consume five or more 
servings of fruit and vegetable per day to 29%.
26.0% 29.0%
By 2016, increase the proportion of high school students who consume 
five or more servings of fruit and vegetables per day to 20%.
19.0% 20.0%
eData sources and baseline not yet determined. 
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Environmental Objectives
Performance Measurese Baseline 2016 Target
By 2016, increase the number of health care providers who have an 
accurate understanding of the role of the environment in general plays 
in cancer risk. 
By 2016, increase the number of consumers who are aware of and 
knowledgeable about naturally occurring and man-made (e.g., indus-
trial, manufacturing) cancer-causing substances in the environment by 
conducting outreach and education activities.
By 2016, increase the number of school officials who are aware of the 
presence of PCB-containing building materials within their  
school buildings.
Infectious Agents Objectives
Performance Measures Baseline 2016 Target
By 2016, increase the rate of complete HPV vaccine immunization (three 
doses) among girls and women 9-26 years old to 80%.
49.4%  80%
By 2016, establish routine vaccination of adolescent and young adult 
males with three doses of HPV vaccine.  
(No baseline – new recommendation and program.)
By 2016, promote age-appropriate sexuality education, inclusive of ways 
of preventing sexually transmitted infection, as part of comprehensive 
health education to a level of 95%. 
Receipt of information about condoms 
Receipt of information about HIV/AIDS
50.0%
89.0%  95.0%
By 2016, reduce the risk of cancer of the liver by preventing chronic 
hepatitis due to the hepatitis B virus (HBV).
By 2016, reduce the risk of cancer of the liver by preventing chronic 
hepatitis due to the hepatitis C virus (HCV).
By 2016, decrease the prevalence of HIV-related cancers (e.g., lymphoma 
and Kaposi’s sarcoma).
By 2016, address prevention of stomach cancer due to infection with  
H. pylori. 
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Early Detection and Screening
Performance Measures Baseline 2016 Target
By 2016, increase the percentage of Massachusetts women ages 50–74 
who have had a mammogram in the past two years to 90%.
 83.6%  90.0%
By 2016, decrease the rate of White, non-Hispanic and Black, non-
Hispanic women diagnosed with late stage (regional and distant) breast 
cancer to 35 per 100,000. 
White non-Hispanic 
Black non-Hispanic
 43.0f
 43.0
35/100,000 
35/100,000
By 2016, increase the percentage of women ages 21 years of age and 
over who have had a Pap test within the past 3 years to 90%.
 84.5%  90.0%
By 2016, decrease the proportion of Black, non-Hispanic women  
diagnosed with late stage (regional and distant) cervical cancer to  
2 per 100,000.
 5.0
 2/100,000
By 2016, increase screening rates for colorectal cancer to 80% for Mas-
sachusetts men and women age 50–75 years.
 63.2%   80%
By 2016, decrease the proportion of White, non-Hispanic and Black, 
non-Hispanic males and women diagnosed with late stage (regional and 
distant) colorectal cancer to 25 per 100,000 for males and 20 per 100,000 
for females. 
White, non-Hispanic males 
Black, non-Hispanic males 
White, non-Hispanic females 
Black, non-Hispanic females
 30.9
 27.7
 23.3
 22.4
25/100,000 
25/100,000 
20/100,000 
20/100,000
By 2016, increase the number of men age 50 years and older who have 
discussed the risk and benefits of prostate cancer screening with their 
health care providers to 78%.  Men at higher risk, such as those of 
African descent or with a family history of prostate cancer, should start 
discussing this issue at age 45.
 71.0%  78.0%
By 2016, decrease lung cancer mortality rates to 59/100,000 for men and 
39/100,000 for women. 
Males 
Females
 65.3
 43.7
59/100,000 
39/100,000
f Incidence, mortality and stage at diagnosis baseline data are from the Massachusetts Cancer Registry (MCR), 2003-2007
Appendix   |   71
gBaseline from the Commission on Cancer.  Massachusetts Cancer Registry will also be used to track progress for the objective and strategies. 
Treatment, Palliation, Survivorship,  
and End of Life
Cancer Survivorship 
Performance Measures Baseline 2016 Target
By 2016, ensure that all cancer survivors in the Commonwealth, includ-
ing disparate populations, have access to appropriate medical, preven-
tive, and dental services.
By 2016, enhance the use of treatment summaries and care plans in 
cancer survivors.
Treatment 
Performance Measures Baseline 2016 Target
By 2016, increase the percentage of cancer patients that receive first 
course of treatment at National Cancer Institute (NCI) - or Commission 
on Cancer (CoC) - accredited hospitals in Massachusetts to 74%.g
72.0% 74.0%
By 2016, assess the enrollment of patients in clinical trials.   Based on this 
number, increase the percentage of patients that are enrolled in a clini-
cal trial to 4%. 
2.0% 4.0%
Palliative Care 
 
Performance Measures Baseline 2016 Target
By 2016, in collaboration with the American Cancer Society, assess com-
pliance with NCI and CoC standards for palliation.
By 2016, inventory palliative care practices and measures at accredited 
Massachusetts facilities.
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End-of-Life Care
Performance Measures Baseline 2016 Target
By 2016, increase hospice services average length of stay to 65  
days statewide.
61 days 65 days
By 2016, increase the percentage of cancer patients who use hospice 
care in the last 90 days of life to 38%.
 36.0%  38.0%
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